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KEY FINDINGS
  Sharing needles/syringes and injecting 
equipment poses a substantial risk to HCV 
transmission among PWID.
  While needle/syringe sharing is low among 
PWID, equipment sharing is far more common.
  Those who have tested positive to HCV 
antibodies are 7.5 times more likely to 
receptively share needles/syringes than those 
who tested negative to HCV antibodies, thereby 
putting themselves at increased risk. 
  Harm minimisation interventions and public 
health messages need to target this behaviour 
to reduce the risk of HCV infection. 
BACKGROUND
Hepatitis C virus (HCV) infection is a major public health 
concern globally, with people who inject drugs (PWID) most 
at risk.  In Australia, injecting drug use accounts for almost 
90% of newly acquired HCV (Kirby Institute, 2014).
Reducing injecting risk behaviours among PWID is critical to 
reducing the ongoing transmission, morbidity and mortality 
of HCV. Reducing injecting risk behaviours can be achieved 
through various harm minimisation interventions including 
needle and syringe programs (NSPs), opiate substitution 
treatment (OST), and education and information delivered as 
health promotion messages through public health services 
and peer education programs.
While the sharing of needles and syringes is considered to 
have the greatest role in HCV transmission, the sharing of 
injection equipment (spoons, filters, tourniquets, water etc) 
has also been shown to be a source of HCV transmission 
(Crofts et al, 2000;  Van Beek et al, 1998, Corsen et al, 2013). 
While the transmission of HCV through injecting equipment 
is lower than needles/syringes the incidence of this type of 
sharing is far higher making this route of transmission an 
important risk behaviour to target. 
In addition to harm minimisation interventions, the importance 
of early diagnosis and reliable feedback of results is thought 
to impact injecting risk behaviour. Work undertaken in the 
USA by Kwiatkowski, Fortuin Corsi et al. (2002) suggest that 
knowledge of one’s serostatus prompts individuals to modify 
their behaviour to avoid infecting others. While findings from 
an Australian study (Aspinall et al, 2013) recorded a small 
reduction in injecting frequency; no reduction in the sharing 
of injecting equipment following a diagnosis of HCV was 
observed. 
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BULLETIN AIMS
The primary objectives of this study were to determine 
the extent of injecting risk behaviours among a typical 
sample of PWID, and to compare the drug use and risk 
behaviours of PWID who reported anti-HCV positive 
and negative results.   
METHOD
The Illicit Drug Reporting System (IDRS) is an annual 
sentinel surveillance monitoring aimed at detecting 
emerging trends in the illicit drug market. Methodology 
is described in full elsewhere (Stafford and Burns, 
2015).  Briefly, a cross-sectional non-probability sample 
of PWID reporting at least monthly illicit drug injection 
in the preceding six months were recruited via needle 
and syringe programs (NPS), peer-referral and street 
press advertising.  Participants were residents in the 
capital city of each Australian State and Territory where 
they were recruited for at least 12 months preceding 
interview and underwent a structured interviewer-
administered survey.   The survey elicited information 
on demographics, drug use, drug markets, health and 
treatment utilisation, blood-borne virus and injecting 
risk.  The interview took ~40 minutes to administer, and 
subjects received AUD$40 for participation.
Self-report was used to assess HCV testing. 
Participants were asked about prior HCV antibody 
testing (anti-HCV), which detects exposure to the virus. 
Questions related to injecting risk behaviour included 
receptive sharing “How many times in the last month 
have you used a needle after someone had already 
used it”, and distributive sharing “How many times 
in the last month has someone used a needle after 
you have used it”.  These variables were collapsed to 
provide dichotomous outcomes yes/no. 
For the purposes of this bulletin we examined a series 
of questions that were included in a HCV testing and 
treatment module in 2013 questionnaire and the section 
on injecting risk behaviours from the same survey. 
Statistical Analysis
Descriptive analyses were undertaken and bivariate 
analyses were conducted using cross tabulations 
for dichotomous variables, and t-tests for continuous 
variables.  
Logistic regression was run to control for potential 
confounding factors such as age, gender, frequency 
of injection (past month) and duration of injecting (in 
years). Alpha level was set as p<0.05.  Results are 
reported in terms of adjusted odds ratios (AOR) and 
95% confidence intervals (95% CI) for categorical 
outcomes, and t-tests for continuous outcomes.  All 
analyses were conducted in SPSS (v22). 
RESULTS
Demographics and sample characteristics
Between June and July 2013, 887 participants were 
recruited.  The sample was a mean age of 40 years 
(SD: 8.86; range 18-66) and 64% were male.  Most 
participants (84%) were unemployed, and more 
than half (56%) of the sample reported a history of 
incarceration.  (Table 1) 
Table 1: Sample characteristics
IDRS  (N=887)
Male 64%
Mean age 40 years
Unemployment 84%
Prison history 56%
Needle/syringe and injecting equipment 
sharing
Needle and syringe sharing among the total sample was 
low with 11% reporting lending a needle to someone 
else after using it themselves (distributive sharing) and 
7% reporting using a needle after someone else had 
used it (receptive sharing).  Seven percent of PWID 
reported receptively sharing needles on a median of 
two occasions in the past month, with typically either 
regular sex partner(s) (48%) or close friend(s) (39%).
Injecting equipment sharing was reported by a much 
larger proportion, almost one quarter of the total 
sample (24%).  Among PWID who shared injecting 
equipment; the sharing of spoons (to prepare mixtures) 
was reported by 75%, the sharing of tourniquets by 
31%, the sharing of water by 26%, and filters by 21%. 
(Table 2).
The majority (90%) of participants had undergone 
Hepatitis C antibody (anti-HCV) testing and of those 
who had been tested, two-thirds (69%) had returned a 
positive result. 
Participants who are anti-HCV positive were older, had 
longer injecting histories, and were more likely to be 
in current opioid substitution treatment therapy (OST) 
compared to the anti-HCV negative group.  They were 
also more likely to nominate heroin as their drug of 
choice and the drug they injected most often in the last 
month.
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Table 2: Needle/Syringe and injecting equipment 
sharing among PWID
IDRS N=887
(n) %
Distributive sharing^ 93 11%
Receptive sharing^ 61 7%
- Shared with regular sex 
partner(s) 26 48%
- Shared with close friend(s) 21 39%
Median # of times receptively 
shared^† 2.0
Shared injecting equipment 214 24%
- Spoons 161 75%
- Tourniquets 67 31%
- Water 55 26%
- Filter 44 21%
^in past month
† among those who reported receptively sharing
HCV testing and injecting risk behaviours
There was no significant difference between those 
who are anti-HCV positive and those who are anti-
HCV negative among people who distributively shared 
(Table 3).  However, participants who are anti-HCV 
positive were 7.5 times more likely to receptively share 
than those who were anti-HCV negative; even after 
controlling for age, gender, length of injecting history 
(years) and frequency of injecting occasions (past 
month). 
Table 3: Needle/Syringe sharing among HCV status 
groups
Anti-HCV 
negative
Anti-HCV 
positive
P 
value
Distributive sharing 9% 11% 0.234
Receptive sharing 2% 9%
DISCUSSION
While needle/syringe sharing is commonly understood 
among PWID to be a significant transmission risk; the 
sharing of injecting equipment is perceived to be less 
risky and is reported by many more individuals. This 
exposes a serious gap in knowledge among PWID and 
presents an opportunity to increase awareness that 
may lead to reducing transmission of HCV and other 
blood-borne virus infections (BBVI).  
Even where the risk of needle/syringe sharing is 
acknowledged, receptive sharing is still reported among 
PWID with a positive result for HCV antibodies. These 
findings are of considerable concern as receptive 
sharing exposes the individual to additional BBVI 
risks including re-infection, infection with a different 
genotype, and/or infection with additional BBVI (i.e. 
HIV).   
However, the majority of participants were actively 
engaged in their health care and most had undergone 
antibody screening for Hepatitis C.  While previous 
studies, Kwiatkowski, Fortuin Corsi et al. (2002) 
suggest that knowledge of one’s serostatus prompts 
individuals to modify their behaviour to avoid infecting 
others; results shown here suggest that rather than 
prompting protective behaviours (reducing distributive 
sharing), individuals with a positive result for anti-
HCV are more likely to use a needle after someone 
else (receptively share) than those who are anti-HCV 
negative.   
Other findings from this data (not presented here) have 
uncovered an ambivalent attitude towards treatment 
efficacy (despite recent advances) among this group 
which may explain, in part, a lack of concern regarding 
additional exposure post-diagnosis. 
CONCLUSION
Harm minimisation strategies and health promotion 
messages need to target these behaviour to educate 
and inform individuals of the additional risks receptive 
sharing and equipment sharing poses. 
P<0.01
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